Harvard Catalyst Profiles

Contact, publication, and social network information about Harvard faculty and fellows.

HMS faculty, help us improve the algorithms in Profiles by uploading your CV!

Isabel Arrillaga-Romany, M.D.

Title
Institution
Department
Address

Bibliographic
Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
  1. Irwin KE, Ko N, Walsh EP, Decker V, Arrillaga-Romany I, Plotkin SR, Franas J, Gorton E, Moy B. Developing a Virtual Equity Hub: Adapting the Tumor Board Model for Equity in Cancer Care. Oncologist. 2022 Jul 05; 27(7):518-524. PMID: 35443045; PMCID: PMC9256021.
    Citations:    Fields:    Translation:Humans
  2. Saraf A, Yock TI, Niemierko A, Oh KS, Curry WT, Butler WE, Arrillaga-Romany I, Ebb DH, Tarbell NJ, MacDonald S, Loeffler JS, Shih HA. Long-term outcomes and late toxicity of adult medulloblastoma treated with combined modality therapy: a contemporary single-institution experience. Neuro Oncol. 2022 Jun 07. PMID: 35671386.
    Citations:    Fields:    
  3. Miller JJ, Cahill DP, Arrillaga-Romany I. Enhancing demethylation-induced differentiation in IDH-mutant glioma. Neuro Oncol. 2022 05 04; 24(5):724-725. PMID: 35239963; PMCID: PMC9071324.
    Citations:    Fields:    Translation:HumansCells
  4. Brastianos PK, Kim AE, Giobbie-Hurder A, Lee EQ, Wang N, Eichler AF, Chukwueke U, Forst DA, Arrillaga-Romany IC, Dietrich J, Corbin Z, Moliterno J, Baehring J, White M, Lou KW, Larson J, de Sauvage MA, Evancic K, Mora J, Nayyar N, Loeffler J, Oh K, Shih HA, Curry WT, Cahill DP, Barker FG, Gerstner ER, Santagata S. Phase 2 study of pembrolizumab in patients with recurrent and residual high-grade meningiomas. Nat Commun. 2022 03 14; 13(1):1325. PMID: 35289329; PMCID: PMC8921328.
    Citations: 3     Fields:    Translation:HumansCTClinical Trials
  5. El-Abtah ME, Wenke MR, Talati P, Fu M, Kim D, Weerasekera A, He J, Vaynrub A, Vangel M, Rapalino O, Andronesi O, Arrillaga-Romany I, Forst DA, Yen YF, Rosen B, Batchelor TT, Gonzalez RG, Dietrich J, Gerstner ER, Ratai EM. Myo-Inositol Levels Measured with MR Spectroscopy Can Help Predict Failure of Antiangiogenic Treatment in Recurrent Glioblastoma. Radiology. 2022 02; 302(2):410-418. PMID: 34751617; PMCID: PMC8805659.
    Citations: 1     Fields:    Translation:Humans
  6. Talati P, El-Abtah M, Kim D, Dietrich J, Fu M, Wenke M, He J, Natheir SN, Vangel M, Rapalino O, Vaynrub A, Arrillaga-Romany I, Forst DA, Yen YF, Andronesi O, Kalpathy-Cramer J, Rosen B, Batchelor TT, Gonzalez RG, Gerstner ER, Ratai EM. MR spectroscopic imaging predicts early response to anti-angiogenic therapy in recurrent glioblastoma. Neurooncol Adv. 2021 Jan-Dec; 3(1):vdab060. PMID: 34131648; PMCID: PMC8193903.
    Citations: 2     
  7. Lim-Fat MJ, Song KW, Iorgulescu JB, Andersen BM, Forst DA, Jordan JT, Gerstner ER, Reardon DA, Wen PY, Arrillaga-Romany I. Clinical, radiological and genomic features and targeted therapy in BRAF V600E mutant adult glioblastoma. J Neurooncol. 2021 May; 152(3):515-522. PMID: 33646525; PMCID: PMC8415171.
    Citations: 2     Fields:    Translation:Humans
  8. Bouffard MA, Chwalisz BK, Romero JM, Arrillaga-Romany IC, Massoth LR. Case 6-2021: A 65-Year-Old Man with Eye Pain and Decreased Vision. N Engl J Med. 2021 Feb 25; 384(8):745-753. PMID: 33626257.
    Citations:    Fields:    Translation:Humans
  9. Park JW, Sahm F, Steffl B, Arrillaga-Romany I, Cahill D, Monje M, Herold-Mende C, Wick W, Turcan S. TERT and DNMT1 expression predict sensitivity to decitabine in gliomas. Neuro Oncol. 2021 01 30; 23(1):76-87. PMID: 32882013.
    Citations: 6     Fields:    Translation:HumansCells
  10. Chi AS, Cahill DP, Reardon DA, Wen PY, Mikkelsen T, Peereboom DM, Wong ET, Gerstner ER, Dietrich J, Plotkin SR, Norden AD, Lee EQ, Nayak L, Tanaka S, Wakimoto H, Lelic N, Koerner MV, Klofas LK, Bertalan MS, Arrillaga-Romany IC, Betensky RA, Curry WT, Borger DR, Balaj L, Kitchen RR, Chakrabortty SK, Valentino MD, Skog J, Breakefield XO, Iafrate AJ, Batchelor TT. Exploring Predictors of Response to Dacomitinib in EGFR-Amplified Recurrent Glioblastoma. JCO Precis Oncol. 2020; 4. PMID: 32923886.
    Citations: 7     Fields:    
  11. Arrillaga-Romany I, Odia Y, Prabhu VV, Tarapore RS, Merdinger K, Stogniew M, Oster W, Allen JE, Mehta M, Batchelor TT, Wen PY. Biological activity of weekly ONC201 in adult recurrent glioblastoma patients. Neuro Oncol. 2020 01 11; 22(1):94-102. PMID: 31702782.
    Citations: 20     Fields:    Translation:HumansCTClinical Trials
  12. Miller JJ, Loebel F, Juratli TA, Tummala SS, Williams EA, Batchelor TT, Arrillaga-Romany I, Cahill DP. Accelerated progression of IDH mutant glioma after first recurrence. Neuro Oncol. 2019 05 06; 21(5):669-677. PMID: 30668823; PMCID: PMC6502499.
    Citations: 13     Fields:    Translation:Humans
  13. Alexander BM, Trippa L, Gaffey S, Arrillaga-Romany IC, Lee EQ, Rinne ML, Ahluwalia MS, Colman H, Fell G, Galanis E, de Groot J, Drappatz J, Lassman AB, Meredith DM, Nabors LB, Santagata S, Schiff D, Welch MR, Ligon KL, Wen PY. Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A Bayesian Adaptive Platform Trial to Develop Precision Medicines for Patients With Glioblastoma. JCO Precis Oncol. 2019; 3. PMID: 32914038; PMCID: PMC7448806.
    Citations: 19     Fields:    
  14. Karschnia P, Jordan JT, Forst DA, Arrillaga-Romany IC, Batchelor TT, Baehring JM, Clement NF, Gonzalez Castro LN, Herlopian A, Maus MV, Schwaiblmair MH, Soumerai JD, Takvorian RW, Hochberg EP, Barnes JA, Abramson JS, Frigault MJ, Dietrich J. Clinical presentation, management, and biomarkers of neurotoxicity after adoptive immunotherapy with CAR T cells. Blood. 2019 05 16; 133(20):2212-2221. PMID: 30808634.
    Citations: 67     Fields:    Translation:Humans
  15. Cloughesy TF, Mochizuki AY, Orpilla JR, Hugo W, Lee AH, Davidson TB, Wang AC, Ellingson BM, Rytlewski JA, Sanders CM, Kawaguchi ES, Du L, Li G, Yong WH, Gaffey SC, Cohen AL, Mellinghoff IK, Lee EQ, Reardon DA, O'Brien BJ, Butowski NA, Nghiemphu PL, Clarke JL, Arrillaga-Romany IC, Colman H, Kaley TJ, de Groot JF, Liau LM, Wen PY, Prins RM. Neoadjuvant anti-PD-1 immunotherapy promotes a survival benefit with intratumoral and systemic immune responses in recurrent glioblastoma. Nat Med. 2019 03; 25(3):477-486. PMID: 30742122; PMCID: PMC6408961.
    Citations: 381     Fields:    Translation:HumansCells
  16. Arrillaga-Romany I, Curry WT, Jordan JT, Cahill DP, Nahed BV, Martuza RL, Loeffler JS, Järhult SJ, Muzikansky A, Cohen AB, Singhal AB, Goldstein JN, Batchelor TT. Performance of a Hospital Pathway for Patients With a New Single Brain Mass. J Oncol Pract. 2019 Mar; 15(3):e211-e218. PMID: 30681891.
    Citations: 1     Fields:    Translation:Humans
  17. Prabhu VV, Madhukar NS, Gilvary C, Kline CLB, Oster S, El-Deiry WS, Elemento O, Doherty F, VanEngelenburg A, Durrant J, Tarapore RS, Deacon S, Charter N, Jung J, Park DM, Gilbert MR, Rusert J, Wechsler-Reya R, Arrillaga-Romany I, Batchelor TT, Wen PY, Oster W, Allen JE. Dopamine Receptor D5 is a Modulator of Tumor Response to Dopamine Receptor D2 Antagonism. Clin Cancer Res. 2019 04 01; 25(7):2305-2313. PMID: 30559168.
    Citations: 20     Fields:    Translation:HumansCells
  18. Ellingson BM, Abrey LE, Nelson SJ, Kaufmann TJ, Garcia J, Chinot O, Saran F, Nishikawa R, Henriksson R, Mason WP, Wick W, Butowski N, Ligon KL, Gerstner ER, Colman H, de Groot J, Chang S, Mellinghoff I, Young RJ, Alexander BM, Colen R, Taylor JW, Arrillaga-Romany I, Mehta A, Huang RY, Pope WB, Reardon D, Batchelor T, Prados M, Galanis E, Wen PY, Cloughesy TF. Validation of postoperative residual contrast-enhancing tumor volume as an independent prognostic factor for overall survival in newly diagnosed glioblastoma. Neuro Oncol. 2018 08 02; 20(9):1240-1250. PMID: 29660006; PMCID: PMC6071654.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  19. Ly KI, Arrillaga-Romany IC. Neurologic Complications of Systemic Anticancer Therapy. Neurol Clin. 2018 08; 36(3):627-651. PMID: 30072074.
    Citations:    Fields:    Translation:Humans
  20. Andronesi OC, Arrillaga-Romany IC, Ly KI, Bogner W, Ratai EM, Reitz K, Iafrate AJ, Dietrich J, Gerstner ER, Chi AS, Rosen BR, Wen PY, Cahill DP, Batchelor TT. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nat Commun. 2018 04 16; 9(1):1474. PMID: 29662077.
    Citations: 53     Fields:    Translation:HumansCTClinical Trials
  21. Abramson JS, McGree B, Noyes S, Plummer S, Wong C, Chen YB, Palmer E, Albertson T, Ferry JA, Arrillaga-Romany IC. Anti-CD19 CAR T Cells in CNS Diffuse Large-B-Cell Lymphoma. N Engl J Med. 2017 08 24; 377(8):783-784. PMID: 28834486.
    Citations: 59     Fields:    Translation:HumansCells
  22. Jordan JT, Miller JJ, Cushing T, Seijo M, Batchelor TT, Arrillaga-Romany IC, Shih HA, Nachtigall LB, Loeffler JS, Dietrich J. Temozolomide therapy for aggressive functioning pituitary adenomas refractory to surgery and radiation: a case series. Neurooncol Pract. 2018 Mar; 5(1):64-68. PMID: 31385986; PMCID: PMC6655410.
    Citations: 3     
  23. Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 May 12. PMID: 28562358.
    Citations:    
  24. Arrillaga-Romany I, Chi AS, Allen JE, Oster W, Wen PY, Batchelor TT. A phase 2 study of the first imipridone ONC201, a selective DRD2 antagonist for oncology, administered every three weeks in recurrent glioblastoma. Oncotarget. 2017 Oct 03; 8(45):79298-79304. PMID: 29108308; PMCID: PMC5668041.
    Citations: 61     Fields:    
  25. Arrillaga-Romany I, Norden AD. Antiangiogenic therapies for glioblastoma. CNS Oncol. 2014; 3(5):349-58. PMID: 25363007.
    Citations: 4     Fields:    Translation:HumansAnimals
  26. Arrillaga-Romany I, Reardon DA, Wen PY. Current status of antiangiogenic therapies for glioblastomas. Expert Opin Investig Drugs. 2014 Feb; 23(2):199-210. PMID: 24320142.
    Citations: 18     Fields:    Translation:HumansAnimals
  27. Arrillaga-Romany IC, Dietrich J. Imaging findings in cancer therapy-associated neurotoxicity. Semin Neurol. 2012 Sep; 32(4):476-86. PMID: 23361490.
    Citations: 5     Fields:    Translation:HumansAnimals
  28. Lee EQ, Arrillaga-Romany IC, Wen PY. Neurologic complications of cancer drug therapies. Continuum (Minneap Minn). 2012 Apr; 18(2):355-65. PMID: 22810132.
    Citations: 7     Fields:    Translation:Humans
  29. Rasetti R, Mattay VS, Stankevich B, Skjei K, Blasi G, Sambataro F, Arrillaga-Romany IC, Goldberg TE, Callicott JH, Apud JA, Weinberger DR. Modulatory effects of modafinil on neural circuits regulating emotion and cognition. Neuropsychopharmacology. 2010 Sep; 35(10):2101-9. PMID: 20555311.
    Citations: 27     Fields:    Translation:HumansCTClinical Trials
  30. Nikulina EM, Arrillaga-Romany I, Miczek KA, Hammer RP. Long-lasting alteration in mesocorticolimbic structures after repeated social defeat stress in rats: time course of mu-opioid receptor mRNA and FosB/DeltaFosB immunoreactivity. Eur J Neurosci. 2008 May; 27(9):2272-84. PMID: 18445218.
    Citations: 38     Fields:    Translation:Animals
Local representatives can answer questions about the Profiles website or help with editing a profile or issues with profile data. For assistance with this profile: HMS/HSDM faculty should contact contactcatalyst.harvard.edu. For faculty or fellow appointment updates and changes, please ask your appointing department to contact HMS. For fellow personal and demographic information, contact HMS Human Resources at human_resourceshms.harvard.edu. For faculty personal and demographic information, contact HMS Office for Faculty Affairs at facappthms.harvard.edu.
Arrillaga-Romany's Networks
Click the
Explore
buttons for more information and interactive visualizations!
Concepts (136)
Explore
_
Co-Authors (70)
Explore
_
Similar People (60)
Explore
_
Same Department 
Explore
_
Physical Neighbors
_
Funded by the NIH National Center for Advancing Translational Sciences through its Clinical and Translational Science Awards Program, grant number UL1TR002541.